Myelofibrosis surgery: Difference between revisions
Jump to navigation
Jump to search
m (Bot: Removing from Primary care) |
|||
| (4 intermediate revisions by 2 users not shown) | |||
| Line 1: | Line 1: | ||
__NOTOC__ | __NOTOC__ | ||
{{Myelofibrosis}} | {{Myelofibrosis}} | ||
{{CMG}}{{AE}}{{SR}} | {{CMG}}{{AE}}{{SR}}{{Sab}} | ||
==Overview== | ==Overview== | ||
[[Surgery]] is not the first-line treatment option for patients with myelofibrosis. [[Splenectomy]] is usually reserved for patients with massive | [[Surgery]] is not the [[first-line treatment]] option for [[Patient|patients]] with [[myelofibrosis]]. [[Splenectomy]] is usually reserved for [[Patient|patients]] with massive [[splenomegaly]] unresponsive to conservative treatment. The only known [[cure]] is [[stem cell transplantation|allogeneic stem cell transplantation]], but this approach involves significant risks. | ||
==Surgery== | ==Surgery== | ||
===Splenectomy=== | ===Splenectomy=== | ||
*Surgery is not the first-line treatment option for patients with myelofibrosis. | *[[Surgery]] is not the [[first-line treatment]] option for [[Patient|patients]] with [[myelofibrosis]]. | ||
*[[Splenectomy]] is usually reserved for patients with massive | *[[Splenectomy]] is usually reserved for [[Patient|patients]] with massive [[splenomegaly]] unresponsive to conservative treatment.<ref>{{cite book | last = Hoffman | first = Ronald | title = Hematology : basic principles and practice | publisher = Elsevier | location = Philadelphia, PA | year = 2018 | isbn = 9780323357623 }}</ref><ref name="pmid30039550">{{cite journal |vauthors=Tefferi A |title=Primary myelofibrosis: 2019 update on diagnosis, risk-stratification and management |journal=Am. J. Hematol. |volume=93 |issue=12 |pages=1551–1560 |date=December 2018 |pmid=30039550 |doi=10.1002/ajh.25230 |url=}}</ref><ref name="pmid29866811">{{cite journal |vauthors=Pardanani A, Tefferi A |title=How I treat myelofibrosis after failure of JAK inhibitors |journal=Blood |volume=132 |issue=5 |pages=492–500 |date=August 2018 |pmid=29866811 |doi=10.1182/blood-2018-02-785923 |url=}}</ref> | ||
*It is associated with postoperative morbidity rate of 15-30% and a mortality rate of 10%. | *It is associated with postoperative [[morbidity]] rate of 15-30% and a [[mortality rate]] of 10%. | ||
===Allogeneic stem cell transplantation=== | ===Allogeneic stem cell transplantation=== | ||
The only known cure is | The only known [[cure]] is [[stem cell transplantation|allogeneic stem cell transplantation]], but this approach involves significant risks.<ref name="pmid15725078">{{cite journal |author=Cervantes F |title=Modern management of myelofibrosis |journal=Br. J. Haematol. |volume=128 |issue=5 |pages=583–92 |year=2005 |month=March |pmid=15725078 |doi=10.1111/j.1365-2141.2004.05301.x |url=http://dx.doi.org/10.1111/j.1365-2141.2004.05301.x}}</ref> | ||
==References== | ==References== | ||
{{reflist|2}} | {{reflist|2}} | ||
[[Category: | [[Category:Medicine]] | ||
[[Category:Hematology]] | [[Category:Hematology]] | ||
[[Category:Oncology]] | [[Category:Oncology]] | ||
[[Category:Neurology]] | [[Category:Neurology]] | ||
[[Category:Neurosurgery]] | [[Category:Neurosurgery]] | ||
[[Category:Up-To-Date]] | |||
Latest revision as of 22:50, 29 July 2020
|
Myelofibrosis Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Case Studies |
|
Myelofibrosis surgery On the Web |
|
American Roentgen Ray Society Images of Myelofibrosis surgery |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]Associate Editor(s)-in-Chief: Sujit Routray, M.D. [2]Sabawoon Mirwais, M.B.B.S, M.D.[3]
Overview
Surgery is not the first-line treatment option for patients with myelofibrosis. Splenectomy is usually reserved for patients with massive splenomegaly unresponsive to conservative treatment. The only known cure is allogeneic stem cell transplantation, but this approach involves significant risks.
Surgery
Splenectomy
- Surgery is not the first-line treatment option for patients with myelofibrosis.
- Splenectomy is usually reserved for patients with massive splenomegaly unresponsive to conservative treatment.[1][2][3]
- It is associated with postoperative morbidity rate of 15-30% and a mortality rate of 10%.
Allogeneic stem cell transplantation
The only known cure is allogeneic stem cell transplantation, but this approach involves significant risks.[4]
References
- ↑ Hoffman, Ronald (2018). Hematology : basic principles and practice. Philadelphia, PA: Elsevier. ISBN 9780323357623.
- ↑ Tefferi A (December 2018). "Primary myelofibrosis: 2019 update on diagnosis, risk-stratification and management". Am. J. Hematol. 93 (12): 1551–1560. doi:10.1002/ajh.25230. PMID 30039550.
- ↑ Pardanani A, Tefferi A (August 2018). "How I treat myelofibrosis after failure of JAK inhibitors". Blood. 132 (5): 492–500. doi:10.1182/blood-2018-02-785923. PMID 29866811.
- ↑ Cervantes F (2005). "Modern management of myelofibrosis". Br. J. Haematol. 128 (5): 583–92. doi:10.1111/j.1365-2141.2004.05301.x. PMID 15725078. Unknown parameter
|month=ignored (help)